Comparative Pharmacology
Head-to-head clinical analysis: CARTEOLOL HYDROCHLORIDE versus LOPRESSOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARTEOLOL HYDROCHLORIDE versus LOPRESSOR.
CARTEOLOL HYDROCHLORIDE vs LOPRESSOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective beta-adrenergic receptor antagonist (beta-blocker) with intrinsic sympathomimetic activity (ISA) and weak local anesthetic (membrane-stabilizing) activity. Reduces intraocular pressure by decreasing aqueous humor production.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors, predominantly in cardiac tissue.
Ophthalmic: Instill 1 drop of 1% or 2% solution into affected eye(s) twice daily. Oral: 2.5 mg to 5 mg once daily; may increase to 10 mg once daily if needed. Maximum dose 10 mg daily.
50 mg orally twice daily, titrate up to 100 mg twice daily as needed.
None Documented
None Documented
Terminal elimination half-life is 5-6 hours in patients with normal renal function; may extend to 24-36 hours in severe renal impairment.
Terminal elimination half-life: 3-7 hours (mean 4.5 h); may be prolonged in hepatic impairment or elderly
Renal excretion of unchanged drug and active metabolite (8-hydroxycarteolol) accounts for 50-70% of elimination. Biliary/fecal excretion is minimal (<10%).
Renal: ~95% (primarily as metabolites, <5% unchanged); fecal: ~5%
Category C
Category C
Beta-Blocker
Beta-Blocker